Table 2.
Comparison of responses with respect to surgeon experience (ie. number of ALPPS performed) and performing ALPPS for non-colorectal liver metastases, performing anatomical variations of ALPPS, recommending neoadjuvant chemotherapy prior to performing ALPPS for CRLM, or performing ALPPS for an FLR over 30%
| 1–5 ALPPS | 6–12 ALPPS | 13 or More ALPPS | p-value | |
|---|---|---|---|---|
| ALPPS for non-CRLM, n (%) | 22 (79) | 19 (86) | 6 (100) | 0.4 |
| Anatomical variation, n (%) | 16 (57) | 16 (73) | 6 (100) | 0.1 |
| Neoadjuvant chemotherapy, n (%) | 18 (64) | 14 (64) | 5 (83) | 0.64 |
| ALPPS for FLR >30%, n (%) | 12 (43) | 13 (59) | 5 (83) | 0.16 |